TCO-amine hydrochloride is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. TCO-amine hydrochloride is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

TCCNeu5Ac (compound H-56) is a high-affinity and selective trisaccharide glycan ligand for Siglec-1 (CD169). TCCNeu5Ac azide can be conjugated to lipids to selectively target cells expressing either murine or human CD169 in vitro, exhibiting in vivo targeting to CD169-positive macrophages. TCCNeu5Ac can be used for in vivo macrophage delivery.

TBC-4746 is a α4β1/α4β7 integrin antagonist. TBC-4746 can be used in the research of asthma and multiple sclerosis.

Tazolol is a specific β-adrenergic antagonist (IC50: 700 nM for (-) isoproterenol-elicited accumulation of cyclic AMP in rat cortical slices). Tazolol produces a significant and sustained increase in cardiac output and stroke volume. Tazolol can be used in the research of heart failure.

Tau ligand-2 is a tau aggregate ligand with a Ki value of 0.99 nM. Radiolabeled (18F) Tau ligand-2 serves as a PET tracer. Tau ligand-2 is applicable to research related to Alzheimer's disease.

Talsupram is a selective noradrenaline inhibitor that has a high affinity for the noradrenaline transporter. Talsupram exhibits anti-hyperalgesic effects. Talsupram can decrease ethanol intake to the levels prior to REM-induced deprivation in rat model.

Talampicillin (hydrochloride) is a ampicillin derivative. Talampicillin (hydrochloride) is a thiazolide carboxylic ester of ampicillin. Talampicillin (hydrochloride) can be studied in research on urinary infection.

Tagorizine is a 5-LOX inhibitor. Tagorizine can be used to study cerebral (or peripheral) blood vessel dilation.

Tafuramycin A, a Duocarmycin derivative, is a potent anticancer and parasite attenuating agent. Tafuramycin A can be used for triple-negative breast cancer (TNBC) and malaria infection research.

TACE-IN-1 is an orally active hydantoin-based tumor necrosis factor-α converting enzyme (TACE) inhibitor. TACE-IN-1 inhibits the production of TNF-α in human whole blood. TACE-IN-1 can be prepared as a stable neutral form. TACE-IN-1 can be used in anti-inflammatory research.

TA-0201 is a novel orally active, competitive, non-peptide endothelin receptor antagonist. TA-0201 antagonizes the specific binding of [125I]ET-1 to cloned human receptors of ETA and ETB with Ki values of 15 pM and 41 nM, respectively. TA-0201 inhibits the pressor response to the exogenous big ET-1.

T3SS-IN-6 is a thiazolidin-2-cyanamide derivative and type III secretion system (T3SS) inhibitor targeting Xanthomonas oryzae pv. oryzae (Xoo). T3SS-IN-6 exhibits no effect on Xoo growth. T3SS-IN-6 shows no measurable acute toxicity to silkworms and earthworms.

T133 is an orally active ATP-competitive mTOR inhibitor with an IC50 of 0.34 nM and a Ki of 0.17 nM. T133 suppresses phosphorylation of AKT, S6K1, and 4EBP1. T133 inhibits cancer cell proliferation and migration, induces apoptosis, cell cycle arrest, and autophagy. T133 exhibits dose-dependent antitumor efficacy in xenograft mouse models. T133 can be used for the research of cancer, such as gastric cancer and lung cancer.

SYK-1106 is a potent delta-opioid receptor (DOR) agonist with an EC50 of 89 pM and a Ki of 848 pM. SYK-1106 is selective for μ and κ opioid receptors, with Ki values of 9.54 nM and 2.45 nM, respectively. SYK-1106 induces dose-dependent antidepressant-like effects. SYK-1106 can be used for the research of depression.

SYAF080 is a human A₂B adenosine receptor (hA₂B AdoR) antagonist with a Ki of 23.6 nM and a KB of 25.2 nM. SYAF080no relevant inhibition of human CYP450 cytochromes. SYAF080 can be used for the research of inflammation, metabolic and cardiovascular disease.

SY-589 is an orally active DNA polymerase Polθ helicase domain inhibitor (IC50=2.29 nM) and DNA damage inducer. SY-589 inhibits the ATPase activity of the Polθ helicase domain and blocks the Polθ-mediated microhomology-mediated end joining (MMEJ) DNA repair pathway (IC50=0.85 nM). SY-589 also induces the accumulation of DNA double-strand breaks by increasing γ-H2AX levels. SY-589 exerts antiproliferative effects on BRCA2-deficient cells and is used in the research of HR-deficient tumors.

SUVN-507 is a 5-HT6 receptor antagonist. SUVN-507 can reverse cognitive impairments and enhance excitatory neural transmission while weakening inhibitory neural transmission. SUVN-507 can be used for the research of neurological disease, such as Alzheimer's disease.

Sumacetamol (SUR 2647) is the N-acetyl-DL-methionine ester of Paracetamol. Sumacetamol is orally active. Sumacetamol enhances the hepatic GSH synthesizing capacity in Bom:NMRI mice after experimental overdosage and offers protection of hepatic cell integrity, when combined with Paracetamol .

Sulofenur (LY186641) is an orally active anti-tumor agent. Sulofenur induces gene expression through calcium ion-dependent pathways and some protein kinase-independent pathways, and its effect is particularly enhanced in H-ras mutant cells. Sulofenur exhibits significant activity in mouse solid tumor models and human tumor xenograft models.

Sulfiflumin (compound I) is a thiazolidine acaricide. Sulfiflumin can be used as a plant protection agent.

Sucrose dilaurate acts as an emulsifier, dispersant and stabilizer. Sucrose dilaurate reduces the release of HMGB1 from UVB-irradiated keratinocytes. Sucrose dilaurate inhibits melanogenesis and decreases bilirubin levels. Sucrose dilaurate induces autophagy in human epidermal keratinocytes, thereby reducing carboxymethyl lysine (CML) levels. Sucrose dilaurate reduces the secretion of insulin-like growth factor-binding protein 3 (IGFBP3) and nerve growth factor (NGF) by senescent keratinocytes. Sucrose dilaurate is investigated as an emulsifier, dispersant or stabilizer in the cosmetics, food and pharmaceutical industries.

SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator. SU212 can selectively induce oxidative phosphorylation, reduce glycolysis activity and glucose uptake in tumor cells, and directly bind to ENO1 without affecting these pathways in normal cells. SU212 induces apoptosis and promotes ENO1 degradation via proteasomal and autophagic pathways without inhibiting the catalytic activity. SU212 leads to mitotic arrest and apoptosis in TNBC (triple-negative breast cancer) cells by activating AMPK, demonstrating potent anti-tumor activity in vitro. SU212 inhibits tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models, exhibiting an excellent safety profile. SU212 can be used in research on t TNBC, diabetes, and fatty liver disease.

STING-IN-17 (compound 10a) is an orally active STING (human STING IC50 = 29 nM, mouse STING IC50 = 15 nM) inhibitor. STING-IN-17 can inhibit the phosphorylation of STING, TBK1 and IRF3. STING-IN-17 dose dependently inhibits the mRNA expression of IP10, IFNB1 and ISG56. STING-IN-17 can reduce ROS and inhibit the expression of cleaved-PARP/caspase-3. STING-IN-17 can improve kidney function. STING-IN-17 can be used for research on inflammatory conditions such as acute kidney injury.

STING agonist-51 (Example 3) is a bis-benzimidazole STING agonist.STING agonist-51 can be used for the research of cancer.

STING agonist-50 is an orally active STING agonist with an IC50 of 3.457 μM. STING agonist-50 activates the STING signaling pathway and promotes the phosphorylation of downstream TBK1 and IRF3. STING agonist-50 induces the expression of IFN-β, CXCL10 and IL-6. STING agonist-50 inhibits tumor growth in syngeneic mouse models. STING agonist-50 can be used for the research of colorectal cancer.

STING agonist-48 is a potent STING agonist that exhibits STING-dependent activity in vitro (EC50 = 4.02 μM). STING agonist-48 prefers to bind with the transmembrane domain (TMD) over the cytosolic cyclic dinucleotide (CDN) domain. STING agonist-48 shows adjuvant efficacy, enhancing IgG and Th1/Th2 cytokine responses in humanized STING mice. STING agonist-48 can be used for the study of inflammation-related diseases.

STIM1-TFR1-IN-1 is a stromal interaction molecule 1 (STIM1)-transferrin receptor 1 (TFR1) protein complex inhibitor with a Kd of 2.18 μM for STIM1-CD protein. STIM1-TFR1-IN-1 blocks STIM1-TFR1 interaction and reduce TFR1-mediated iron uptake activity. STIM1-TFR1-IN-1 inhibits ferroptosis, lipid peroxidation and ROS production, enhances glutathione peroxidase 4 (GPX4) activity and glutathione/oxidized glutathione ratio, and rescues ferroptosis-associated mitochondrial morphological changes. STIM1-TFR1-IN-1 exhibits neuroprotectiveeffects and reduces brain injury. STIM1-TFR1-IN-1 can be used for the research of intracerebral hemorrhage.

Stibophen is a potent antiparasitic agent is effective against Litomosoides carinii, Dipetalonema witei, and Brugia pahangi. Stibophen inhibits lactate accumulation and phosphofructokinases (PFK) activity in adult filariids. Stibophen also inhibits Ascaris and Hymenolepis diminuta PFK without inhibiting mammalian liver PFK. Stibophen can be used for the research of schistosomiasis and filariid infections.

Steroid sulfatase-IN-11 is a steroid sulfatase inhibitor, which functionally inhibits steroid sulfatase activity, reducing the enzyme's ability to hydrolyze steroid sulfates. Steroid sulfatase-IN-11 can be used for the research of hormone-dependent cancers.

STAT6-IN-11 (example 3) is a STAT6 inhibitor with an EC50 of 6 nM. STAT6-IN-11 inhibits CCL17 secretion in peripheral human whole blood, stimulated through the IL-13-IL- 13 receptor/IL-4 receptor pathway, with an IC50 of 83 nM. STAT6-IN-11 can be used for the study of dermatological condition or a respiratory condition.